AG
AVIR icon

Algert Global’s Atea Pharmaceuticals AVIR Stock Holding History

Algert Global’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,199
Closed -$82K – 1142
2025
Q3 		$82K Sell
28,199
-2,440
-8% -$8.33K ﹤0.01% 1095
2025
Q2 		$110K Hold
30,639
– – ﹤0.01% 1134
2025
Q1 		$92K Buy
30,639
+3,240
+12% +$10.1K ﹤0.01% 1133
2024
Q4 		$92K Hold
27,399
– – ﹤0.01% 1123
2024
Q3 		$92K Buy
27,399
+3,102
+13% +$11.2K ﹤0.01% 1122
2024
Q2 		$80K Buy
24,297
+1,237
+5% +$4.61K ﹤0.01% 1415
2024
Q1 		$93K Sell
23,060
-13,840
-38% -$54.2K ﹤0.01% 1018
2023
Q4 		$113K Sell
36,900
-13,610
-27% -$41.2K ﹤0.01% 1062
2023
Q3 		$152K Buy
50,510
+2,230
+5% +$7.59K 0.01% 993
2023
Q2 		$181K Buy
48,280
+24,039
+99% +$90K 0.01% 997
2023
Q1 		$81K Buy
24,241
+2,617
+12% +$10.6K ﹤0.01% 1093
2022
Q4 		$104K Hold
21,624
– – 0.01% 1069
2022
Q3 		$123K Sell
21,624
-3,832
-15% -$29.3K 0.01% 1090
2022
Q2 		$181K Buy
+25,456
New +$174K 0.01% 1041

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Algert Global's AVIR Position: Q4 2025 in Review

Algert Global sold out of Atea Pharmaceuticals (AVIR) in Q4 2025, closing a stake of 28,199 shares — an estimated $82K sold.

Algert Global first reported a position in AVIR in Q2 2022 and held it in 14 quarters. The position peaked at $181K in Q2 2023. 111 funds tracked by Wall St. Rank hold AVIR as of Q4 2025.

  • Algert Global reported no remaining Atea Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Algert Global sold 28,199 Atea Pharmaceuticals shares in Q4 2025, an estimated $82K.
  • Algert Global first reported a position in Atea Pharmaceuticals in Q2 2022 and held it in 14 quarters.
  • Algert Global's Atea Pharmaceuticals position peaked at $181K in Q2 2023.
  • 111 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.